Today, Nuwellis, Inc. (NASDAQ: NUWE) stock is seeing a significant increase following the announcement that the recently introduced QUELIMMUNE medication had successfully treated its first patient. The stock of NUWE was up 23.24% to $2.97 as of the most recent update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
First Patient Treated with QUELIMMUNE Therapy
Nuwellis announced that the inaugural patient received QUELIMMUNE therapy in a commercial setting at Cincinnati Children’s Hospital. QUELIMMUNE, created by SeaStar Medical and exclusively licensed for distribution in U.S. pediatric hospitals by Nuwellis, is an innovative treatment for pediatric patients (weighing 10 kg or more) afflicted with acute kidney injury (AKI) and sepsis, requiring kidney replacement therapy (KRT).
Dr. Stuart Goldstein, Director of the Center for Acute Care Nephrology at Cincinnati Children’s and Principal Investigator of the multi-center studies leading to FDA clearance of QUELIMMUNE, supervised the administration of the therapy. Regarding the possible advantages of the treatment, Dr. Goldstein was upbeat.
A Transformative Approach
QUELIMMUNE presents a potentially transformative approach to lessen the severe consequences of cytokine storms brought on by AKI and sepsis. About 4,000 children patients with AKI are admitted to hospitals in the United States each year.
QUELIMMUNE aims to address the underlying immune dysregulation in these patients, striving to reduce the incidence and severity of cytokine storms, thus representing a major advancement in the treatment of AKI and sepsis.
Nuwellis’ introduction of QUELIMMUNE to critically ill pediatric patients is a pivotal step in its mission to advance pediatric care. Through its partnership with SeaStar Medical, Nuwellis is dedicated to delivering this groundbreaking therapy to U.S. healthcare providers, offering new hope to children enduring severe immune system reactions.
Prudent Financial Decisions
Nuwellis has signed a formal securities purchase agreement with certain institutional investors, a financial strategy that involves selling 469,340 shares of its common stock at $4.24 per share in a registered direct offering that is priced at-market in accordance with Nasdaq regulations.
In parallel, Nuwellis will conduct a private placement of warrants, which will enable investors to buy up to 938,680 shares of common stock at $3.99 per share upon execution. These warrants have a five-year validity period and can be exercised right away upon issuing.
These financial tactics demonstrate Nuwellis’ dedication to advancing its pediatric business growth plan and strengthening its ability to provide the market with cutting-edge treatments.
